The IBOGAINE Act aims to accelerate the development and access to psychedelic drugs for treating serious mental illnesses.
The IBOGAINE Act, or Initiating Biomedical Outcomes to Garner Advancements into Innovative Neuroplastogen Efficacy Act, seeks to expedite the development and access to psychedelic drugs for treating serious mental illnesses. The bill prioritizes collaboration with the private sector to increase clinical trial participation and data sharing. It also establishes a program to facilitate the timely evaluation and approval of drugs, including psychedelic drugs, by the Food and Drug Administration.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
Analyze for Free
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.